Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-11 Antifibrotics
| Nintedanib |
|
Formulary
|
Ofev® 100mg soft capsule / 150mg soft capsules Only Ofev brand is licensed for IPF NICE TA379 - Nintedanib for treating idiopathic pulmonary fibrosis NICE TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases NICETA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted |
 MHRA: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases NICE TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted |
|
| Pirfenidone |
|
Formulary
|
267mg tablets / hard capsules, 534mg tablets, 801mg tablets |
|
MHRA Drug Safety Update Nov 2020: Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
|
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Asthma action plan child: Asthma UK- Asthma management plan: Asthma UK
- LSCMMG: Asthma Treatment Guideline for Adults
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: Chronic Obstructive Pulmonary Disease (COPD) Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA Drug Safety Update July 2016: N-acetylcysteine: risk of false-low biochemistry test results due to interference with Siemens assays
- MHRA Drug Safety Update Nov 2020: Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- MHRA: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
- NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases
- NICE TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted